PMA device
IMMULITE 2000 Free PSA
Siemens Medical Solutions Diagnostics Limited · Test, Prostate Specific Antigen, Free, (Noncomplexed) To Distinguish Prostate Cancer From Benign Conditions (MTG, Class III) · First FDA decision Apr 21, 2026, newest Apr 21, 2026Prostate cancer
Last checked: Nov 20, 2026Source: FDA, CMS, ClinicalTrials.gov, PubMed
FDA decisions
1
PMA pathway
Device trials
0
Naming "IMMULITE 2000"
MAUDE reports
1,340
Brand "IMMULITE 2000", since 2015
PubMed studies
301
Mentioning "IMMULITE 2000"
AI summary across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, MAUDE and PubMed data on this page, plus web searches for payment facts.
Product review deck
A slide deck reviewing IMMULITE 2000 Free PSA
About ten slides on the technology, clinical evidence, regulatory history and commercialization, built with AI from the data on this page and web research, with sources. Download it as PowerPoint to edit or as PDF to share.
- Executive summary and key facts
- Technology
- Clinical evidence and trials
- Regulatory history and safety
- Reimbursement, market and competition
- Risks, outlook and sources
AI-written from public data and may contain mistakes. Check each fact against its source before relying on it. Not investment, legal, reimbursement or medical advice.
FDA decisions
The newest 1 of 1 decisions filed under this name.
- IMMULITE 2000 Free PSAPMA supplement
P060005-S024 · Decided Apr 21, 2026 · 203 days after receipt · Normal 180 Day Track No User Fee
Device type: Test, prostate specific antigen, free, (noncomplexed) to distinguish prostate cancer from benign conditions (MTG) · Laboratory Medicine & Pathology
Medicare coverage
National and local coverage documents whose titles match this device or its device type. Payment add-ons (NTAP, pass-through, TCET) and likely codes are covered in the summary above.
- Prostate Specific Antigen (Addition of ICD-9-CM 600.00, Hypertrophy (benign) of Prostate Without Urinary Obstruction, as a covered indication)Coding analysisReview closedCAG-00326NUpdated Sep 15, 2026
- Prostate Specific AntigenNational determinationOn the books190.31Updated Oct 1, 2026
- Prostate Specific Antigen (Inclusion of ICD-9-CM Code 600.01 for BPH with Urine Obstruction)Coding analysisReview closedCAG-00232NUpdated Sep 15, 2026
- Autologous Cellular Immunotherapy Treatment of Metastatic Prostate CancerNational analysisReview closedCAG-00422NUpdated Nov 19, 2026
- Abarelix for the Treatment of Prostate CancerNational analysisReview closedCAG-00238NUpdated Sep 15, 2026
- PSA (Addition of ICD-9-CM 600.21, Benign localized hyperplasia of prostate with urinary obstruction as a covered indication)Coding analysisReview closedCAG-00332NUpdated Sep 15, 2026
- Cryosurgical Salvage Therapy for Recurrent Prostate CancerNational analysisReview closedCAG-00064NUpdated Sep 14, 2026
- Cryosurgery Ablation for Prostate CancerNational analysisReview closedCAG-00031NUpdated Sep 14, 2026
Clinical trials
Device studies on ClinicalTrials.gov that name "IMMULITE 2000", any status and sponsor, newest update first.
No registered device study names "IMMULITE 2000".
Adverse event reports (MAUDE)
Reports received since 2015 naming the brand "IMMULITE 2000", and for the whole product code for context.
This brand
1,340 reports: 1,333 malfunction, 7 injury, 0 death
Whole product code MTG
108 reports: 107 malfunction, 1 injury, 0 death
Newest reports for this brand
- IMMULITE 2000 XPi Immunoassay SystemMalfunction
Siemens Healthcare Diagnostics Products, Limited
1219913-2026-00196 · Received Oct 22, 2026 · Event dated Sep 28, 2026
Device type: Analyzer, Chemistry (Photometric, Discrete), For Clinical Use (JJE)
Device problem as coded: Smoking
Patient problem as coded: No Clinical Signs, Symptoms or Conditions
- IMMULITE 2000 Immunoassay SystemMalfunction
Siemens Healthcare Diagnostics Products, Limited
1219913-2026-00191 · Received Oct 15, 2026 · Event dated Sep 25, 2026
Device type: Analyzer, Chemistry (Photometric, Discrete), For Clinical Use (JJE)
Device problem as coded: Smoking
Patient problem as coded: No Clinical Signs, Symptoms or Conditions
- IMMULITE 2000 IGF-IMalfunction
Siemens Healthcare Diagnostics Inc.
1219913-2026-00186 · Received Oct 12, 2026 · Event dated Sep 10, 2026
Device type: Radioimmunoassay, Human Growth Hormone (CFL)
Device problem as coded: Low Test Results
Patient problem as coded: No Clinical Signs, Symptoms or Conditions
2 more reports with a free account
Recalls
From FDA's recall database. FDA lists each recalled product separately, so one recall can appear several times. A recall is often a correction or a labeling change, not a removal from the market.
No recall in FDA's data is linked to these FDA numbers.
Published research
The most relevant PubMed records for "IMMULITE 2000"[tiab]. The summary above synthesizes these.
- Biotin Interference in Assays for Thyroid Hormones, Thyrotropin and Thyroglobulin.
Ylli D, Soldin SJ, Stolze B, et al. · Thyroid · 2021Research Support, Non-U.S. Gov't
- Hair Cortisol Measurement by an Automated Method.
Gonzalez D, Jacobsen D, Ibar C, et al. · Sci Rep · 2019Research Support, Non-U.S. Gov't
- Immunofluorescence vs immunochemiluminescent methods: AIA 2000 vs Immulite 2000.
Cosma C, Baggio S, Casarotti A, et al. · Clin Biochem · 2015Comparative Study
- Acromegaly and pregnancy: a prospective study.
Dias M, Boguszewski C, Gadelha M, et al. · Eur J Endocrinol · 2014Research Support, Non-U.S. Gov't
- Performance characteristics of six homocysteine assays.
La'ulu SL, Rawlins ML, Pfeiffer CM, et al. · Am J Clin Pathol · 2008Comparative Study, Evaluation Study
- Performance characteristics of eight estradiol immunoassays.
Yang DT, Owen WE, Ramsay CS, et al. · Am J Clin Pathol · 2004Comparative Study, Research Support, Non-U.S. Gov't
- Urinary corticoid to creatinine ratios using IMMULITE 2000 XPi for diagnosis of canine hypercortisolism.
Nagata N, Sawamura H, Morishita K, et al. · J Vet Med Sci · 2022
- Development of a Web App to Convert Blood Insulin Concentrations among Various Immunoassays Used in Horses.
Delarocque J, Feige K, Carslake HB, et al. · Animals (Basel) · 2023
- Using Capillary Whole Blood to Quantitatively Measure Ferritin: A Validation Trial of a Point-of-Care System.
Fiddler JL, McBurney MI, Haas JD · Nutrients · 2023
- Comparability of C-Peptide Measurements - Current Status and Clinical Relevance.
Hörber S, Orth M, Fritsche A, et al. · Exp Clin Endocrinol Diabetes · 2023Comparative Study
- Clinical evaluation of the ADVIA Centaur XPT chemiluminescent immunoassay for equine insulin measurement.
Rey-Conejo R, Toribio RE, Möller S, et al. · J Equine Vet Sci · 2025
- Total observed error, total allowable error, and QC rules for canine serum and urine cortisol achievable with the Immulite 2000 Xpi cortisol immunoassay.
Korchia J, Freeman KP · J Vet Diagn Invest · 2022
Other devices of this type
Also filed under product code MTG.
- Elecsys free PSA, free PSA CalSetRoche Diagnostics Corp. · PMA 2023
- Access Hybritech free PSABeckman Coulter, Inc. · PMA 2025
- ARCHITECT Free PSAAbbott Laboratories · PMA 2020
- Dimension FPSA Flex Reagent CartridgeSiemens Healthcare Diagnostics · PMA 2018
- Dimension Vista Fpsa AssaySiemens Healthcare Diagnostics · PMA 2016
- Axsym Free PsaAbbott Laboratories · PMA 2011
- Immulite/Immulite 1000 & Immulite 2000 Free PsaSiemens Medical Solutions Diagnostics Limited · PMA 2010
- Atellica IM free PSA II (fPSAII)Siemens Healthcare Diagnostics, Inc. · PMA 2026
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.